Recombinant Vaccines Against Retrovirus Associated With

$0Z01FY2002AINIH

Niaid Extramural Activities

Investigators

Linked publications, trials & patents

Paper 22234262 Paper 19420086 Paper 18160013 Paper 18155813 Paper 18048074 Paper 17954572 Paper 17698160 Paper 17579577 Paper 17499326 Paper 17360078 Paper 17201662 Paper 16740288 Paper 16725169 Paper 16472543 Paper 16409123 Paper 16267024 Paper 16083934 Paper 16023165 Paper 15858010 Paper 15780866 Paper 15731219 Paper 15725752 Paper 15710048 Paper 15671796 Paper 15650426 Paper 15380355 Paper 15367588 Paper 15315833 Paper 15249657 Paper 15242543 Paper 15242542 Paper 15161069 Paper 15096611 Paper 15070762 Paper 15047809 Paper 15014500 Paper 14963123 Paper 14585221 Paper 14551889 Paper 12970455 Paper 12869693 Paper 12477888 Paper 12477823 Paper 12388710 Paper 12097599 Paper 12097576 Paper 12021371 Paper 12021347 Paper 12009868 Paper 11983252 Paper 11752436 Paper 11393868 Paper 11333896 Paper 11160750 Paper 11134278 Paper 10779808 Paper 10775580 Paper 10684290 Paper 10684264 Patent 9879231 Patent 9453239 Patent 9254319 Patent 9133480 Patent 9133478 Patent 8916172 Patent 8623379 Patent 8124105 Patent 7867982 Patent 7795017 Patent 7560116 Patent 7303754

Abstract

Human immunodeficiency virus (HIV) infection is the determining factor in the development of acquired immunodeficiency syndrome (AIDS). At present there is no effective vaccine against this disease. The objectives of this project are to characterize HIV antigens, determine the targets of humoral and cell mediated immunity, and to use this information to develop candidate vaccines. We have constructed recombinant vaccinia viruses containing genetic information of HIV and the closely related simian immunodeficiency virus. These recombinant viruses have been used to prepare purified immunogens, monoclonal antibodies, targets for cytotoxic T cells and candidate vaccines

View original record on NIH RePORTER →